Soligenix achieves milestone with bivalent and trivalent filovirus vaccines

Soligenix announced two-year stability of its thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees Celsius (104 degrees Fahrenheit) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use. This follows the previous successful demonstration of 100% protection of non-human primates against lethal Sudan ebolavirus and Marburg marburgvirus challenge with the bivalent vaccine. This important milestone is part of an ongoing collaboration with the University of Hawaii at Mnoa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability, including vaccines for Sudan ebolavirus and Marburg marburgvirus. It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the United States Administration’s initiative for pandemic preparedness.